Targeting TAp63 in Breast Cancer.

Citation metadata

Author: Leif W. Ellisen
Date: June 2021
From: Oncology(Vol. 35, Issue 6)
Publisher: Intellisphere, LLC
Document Type: Interview
Length: 2,583 words
Lexile Measure: 1580L

Document controls

Main content

Article Preview :

LEARNING OBJECTIVES

Upon successful completion of this activity, you should be better prepared to:

* Describe the physiologic function of TAp63 in breast cancer

* Explain the rationale for targeting TAp63 as a mechanism for treating breast cancer

RELEASE DATE: June 1, 2021

EXPIRATION DATE: June 1, 2022

INSTRUCTIONS FOR PARTICIPATION/HOW TO RECEIVE CREDIT

1. Read this activity in its entirety.

2. Go to https://www.gotoper.com/go/targeting21tap63 to access and complete the posttest.

3. Answer the evaluation questions.

4. Request credit using the drop-down menu.

You may immediately download your certificate.

FACULTY, STAFF, AND PLANNERS' DISCLOSURES

In accordance with ACCME Guidelines, PER[R] has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Disclosures (Dr. Ellisen): Leif W. Ellisen, MD, PhD, has no relevant financial relationships with commercial interests. The staff of PER[R] have no relevant financial relationships with commercial interests to disclose.

OFF-LABEL DISCLOSURE AND DISCLAIMER

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this activity is for accredited continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER[R] or any of the companies that provided commercial support for this activity.

This activity is funded by PER[R].

ACCREDITATION/CREDIT DESIGNATION

Physicians' Education Resource[R], LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource[R], LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits[TM]. Physicians should claim only the credit commensurate with the extent of their participation in the activity

ACTIVITY

p63 is a member of the p53 tumor suppressor family of transcription factors. (1,2) The TP63 gene encodes for multiple isoforms including TAp63, a full-length isoform that contains a p53-like transactivation (TA) domain, and [DELTA]Np63, an N-terminal truncated isoform. Both isoforms are involved in oncogenesis, but they exert distinct and often antagonistic functions. (1,2) [DELTA]Np63 is an oncogenic driver, whereas TAp63 acts primarily as a tumor suppressor in different cancers including breast cancer.

TAp63 is either undetectable or expressed at very low levels in different types of tumor tissue, including invasive and metastatic lesions of mammary carcinoma. (2) Gain-of-function studies in cancer cell lines demonstrated that TAp63 overexpression induces cell-cycle arrest and cell death. (3) The TP63 gene is rarely mutated in cancer; however, in squamous cell carcinoma TP63 mutations are located in the TA domain, suggesting that TAp63 might be involved in tumor suppression. (4) In triple-negative breast cancer tumor samples, TAp63 expression was associated with androgen receptor, BRCA1/2 wild-type status, and phosphatase and tensin homolog (PTEN) positivity. (5) Furthermore, patients with TAp63 expression had lower rates of disease recurrence and improved overall...

Source Citation

Source Citation   

Gale Document Number: GALE|A677572512